BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

912 related articles for article (PubMed ID: 26879355)

  • 1. Early Remission Is a Realistic Target in a Majority of Patients with DMARD-naive Rheumatoid Arthritis.
    Rannio T; Asikainen J; Kokko A; Hannonen P; Sokka T
    J Rheumatol; 2016 Apr; 43(4):699-706. PubMed ID: 26879355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
    van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
    Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
    J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with seronegative RA have more inflammatory activity compared with patients with seropositive RA in an inception cohort of DMARD-naïve patients classified according to the 2010 ACR/EULAR criteria.
    Nordberg LB; Lillegraven S; Lie E; Aga AB; Olsen IC; Hammer HB; Uhlig T; Jonsson MK; van der Heijde D; Kvien TK; Haavardsholm EA;
    Ann Rheum Dis; 2017 Feb; 76(2):341-345. PubMed ID: 27094444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disease Characteristics and Rheumatoid Arthritis Development in Patients with Early Undifferentiated Arthritis: A 2-year Followup Study.
    Brinkmann GH; Norli ES; Kvien TK; Haugen AJ; Grøvle L; Nygaard H; Bjørneboe O; Thunem C; Mjaavatten MD; Lie E
    J Rheumatol; 2017 Feb; 44(2):154-161. PubMed ID: 28089976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T; Asikainen J; Hannonen P; Yli-Kerttula T; Ekman P; Pirilä L; Kuusalo L; Mali M; Puurtinen-Vilkki M; Kortelainen S; Paltta J; Taimen K; Kauppi M; Laiho K; Nyrhinen S; Mäkinen H; Isomäki P; Uotila T; Aaltonen K; Kautiainen H; Sokka T
    Scand J Rheumatol; 2017 Nov; 46(6):425-431. PubMed ID: 28367663
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
    Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
    Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achievement of Remission and Low Disease Activity Definitions in Patients with Rheumatoid Arthritis in Clinical Practice: Results from the NOR-DMARD Study.
    Uhlig T; Lie E; Norvang V; Lexberg ÅS; Rødevand E; Krøll F; Kalstad S; Olsen IC; Kvien TK
    J Rheumatol; 2016 Apr; 43(4):716-23. PubMed ID: 26879358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort.
    Gossec L; Paternotte S; Combe B; Meyer O; Dougados M
    J Rheumatol; 2014 Jan; 41(1):41-6. PubMed ID: 24241481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
    Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
    Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of Diagnostic and Treatment Delay in Seronegative Rheumatoid Arthritis: Missing the Window of Opportunity.
    Coffey CM; Crowson CS; Myasoedova E; Matteson EL; Davis JM
    Mayo Clin Proc; 2019 Nov; 94(11):2241-2248. PubMed ID: 31619364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
    Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
    J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of rheumatoid arthritis defined according to the 2010-classification criteria.
    Burgers LE; van Nies JA; Ho LY; de Rooy DP; Huizinga TW; van der Helm-van Mil AH
    Ann Rheum Dis; 2014 Feb; 73(2):428-32. PubMed ID: 23661495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of anti cyclic citrullinated peptide antibodies in Malaysian rheumatoid arthritis patients and its correlation with disease activity.
    Sockalingam S; Khuan CS; Sthaneshwar P
    Int J Rheum Dis; 2009 Sep; 12(3):211-5. PubMed ID: 20374348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis in Korean patients with undifferentiated arthritis.
    Jung SJ; Kang Y; Ha YJ; Lee KH; Lee SW; Lee SK; Park YB
    Scand J Rheumatol; 2012 May; 41(3):192-5. PubMed ID: 22401568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining anti-cyclic citrullinated peptide with the American College of Rheumatology 1987 criteria failed to improve early rheumatoid arthritis diagnosis in the community-based very early arthritis cohort.
    Le Loët X; Strotz V; Lequerré T; Boumier P; Pouplin S; Mejjad O; Daragon A; Jouen F; Vittecoq O; Fardellone P; Ménard JF
    Rheumatology (Oxford); 2011 Oct; 50(10):1901-7. PubMed ID: 21750000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
    Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
    Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Five-year outcomes of probable rheumatoid arthritis treated with methotrexate or placebo during the first year (the PROMPT study).
    van Aken J; Heimans L; Gillet-van Dongen H; Visser K; Ronday HK; Speyer I; Peeters AJ; Huizinga TW; Allaart CF
    Ann Rheum Dis; 2014 Feb; 73(2):396-400. PubMed ID: 23334213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.